Connection

Michael Zile to Enalapril

Back to Details
This is a "connection" page, showing publications Michael Zile has written about Enalapril.
Michael Zile
Connection Strength
5.451
Enalapril
  1. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 05; 11(5):e004446.
    View in: PubMed
    Score: 0.562
  2. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 06; 68(22):2425-2436.
    View in: PubMed
    Score: 0.510
  3. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.
    View in: PubMed
    Score: 0.175
  4. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. Circ Heart Fail. 2021 03; 14(3):e008052.
    View in: PubMed
    Score: 0.171
  5. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
    View in: PubMed
    Score: 0.170
  6. Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail. 2020 11; 22(11):2056-2064.
    View in: PubMed
    Score: 0.166
  7. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.
    View in: PubMed
    Score: 0.154
  8. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.
    View in: PubMed
    Score: 0.151
  9. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients?With HFrEF. J Am Coll Cardiol. 2019 02 26; 73(7):795-806.
    View in: PubMed
    Score: 0.149
  10. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019 03; 21(3):337-341.
    View in: PubMed
    Score: 0.148
  11. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. JAMA Cardiol. 2018 12 01; 3(12):1226-1231.
    View in: PubMed
    Score: 0.146
  12. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 07; 6(7):547-554.
    View in: PubMed
    Score: 0.140
  13. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 04; 11(4):e004745.
    View in: PubMed
    Score: 0.140
  14. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2018 04; 20(4):760-768.
    View in: PubMed
    Score: 0.138
  15. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug; 10(8).
    View in: PubMed
    Score: 0.133
  16. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 05; 5(5):333-340.
    View in: PubMed
    Score: 0.130
  17. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J. 2017 Jun; 188:35-41.
    View in: PubMed
    Score: 0.130
  18. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 01 01; 2(1):79-85.
    View in: PubMed
    Score: 0.128
  19. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017 01; 19(1):129-137.
    View in: PubMed
    Score: 0.127
  20. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiol. 2016 09 01; 1(6):666-72.
    View in: PubMed
    Score: 0.125
  21. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Circ Heart Fail. 2016 09; 9(9).
    View in: PubMed
    Score: 0.125
  22. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016 Oct; 18(10):1228-1234.
    View in: PubMed
    Score: 0.123
  23. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 06; 9(6).
    View in: PubMed
    Score: 0.123
  24. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016 Jun 07; 133(23):2254-62.
    View in: PubMed
    Score: 0.122
  25. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail. 2016 Mar; 9(3):e002744.
    View in: PubMed
    Score: 0.121
  26. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016 Jan; 9(1).
    View in: PubMed
    Score: 0.119
  27. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015 Nov 10; 66(19):2059-2071.
    View in: PubMed
    Score: 0.118
  28. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015 Aug 07; 36(30):1990-7.
    View in: PubMed
    Score: 0.115
  29. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan 06; 131(1):54-61.
    View in: PubMed
    Score: 0.111
  30. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11):993-1004.
    View in: PubMed
    Score: 0.109
  31. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014 Jul; 16(7):817-25.
    View in: PubMed
    Score: 0.107
  32. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013 Sep; 15(9):1062-73.
    View in: PubMed
    Score: 0.099
  33. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. Circ Heart Fail. 2023 03; 16(3):e010111.
    View in: PubMed
    Score: 0.049
  34. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.
    View in: PubMed
    Score: 0.047
  35. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 09; 24(9):1591-1598.
    View in: PubMed
    Score: 0.045
  36. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 06 01; 3(6):498-505.
    View in: PubMed
    Score: 0.035
  37. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018 06; 6(6):489-498.
    View in: PubMed
    Score: 0.035
  38. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.034
  39. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017 04 14; 38(15):1132-1143.
    View in: PubMed
    Score: 0.033
  40. Efficacy of Sacubitril/Valsartan Relative to?a Prior Decompensation: The PARADIGM-HF Trial. JACC Heart Fail. 2016 10; 4(10):816-822.
    View in: PubMed
    Score: 0.031
  41. The risk of death associated with proteinuria in heart failure is restricted to patients with an elevated blood urea nitrogen to creatinine ratio. Int J Cardiol. 2016 Jul 15; 215:521-6.
    View in: PubMed
    Score: 0.030
  42. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015 Feb 14; 36(7):434-9.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.